Zeo ScientifiX (ZEOX) 10-Q 17 Mar 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Jan. 31, 2023	Mar. 16, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jan. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--10-31
Entity File Number	000-55008
Entity Registrant Name	Organicell Regenerative Medicine, Inc.
Entity Central Index Key	0001557376
Entity Tax Identification Number	47-4180540
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3321 College Avenue
Entity Address, Address Line Two	Suite 246
Entity Address, City or Town	Davie
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33314
City Area Code	888
Local Phone Number	963-7881
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,490,677,642

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jan. 31, 2023	Oct. 31, 2022
Current Assets
Cash	$ 1,422,501	$ 3,753,097
Accounts receivable, net of allowance for bad debts	106,895	55,110
Receivables from related party	118,939	128,939
Other receivables	8,000	7,433
Prepaid expenses	214,727	173,152
Inventories	281,344	248,510
Funds held in escrow for share repurchase	500,000
Total Current Assets	2,652,406	4,366,241
Property and equipment, net	1,543,833	1,683,516
Other assets – right of use	91,157	110,995
Security deposits	30,400	39,936
TOTAL ASSETS	4,317,796	6,200,688
Current Liabilities
Accounts payable and accrued expenses	2,268,356	2,378,531
Advances payable	220,897	220,897
Finance lease obligations	124,525	143,748
Operating lease obligations	83,971	82,407
Deferred revenue	4,195
Promissory Note, net of debt discount		563,111
Commitment Fee Shortfall Obligation	223,847	174,462
Commitment to repurchase shares in connection with settlement of litigation	500,000	500,000
Total Current Liabilities	3,425,791	4,063,156
Long term finance lease obligations	207,808	220,340
Long term operating lease obligations	7,186	28,588
Total Liabilities	3,640,785	4,312,084
Stockholders’ Equity
Common stock, $0.001 par value, 2,500,000,000 shares authorized; 1,488,757,718 and 1,479,126,390 shares issued and outstanding, respectively	1,488,757	1,479,126
Additional paid-in capital	51,996,216	50,930,784
Accumulated deficit	(52,807,962)	(50,521,306)
Total Stockholders’ Equity	677,011	1,888,604
TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ EQUITY	4,317,796	6,200,688
Series C Preferred Stock [Member]
Shares Subject To Possible Redemption
Preferred stock value

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jan. 31, 2023	Oct. 31, 2022
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	1,488,757,718	1,479,126,390
Common stock, shares outstanding	1,488,757,718	1,479,126,390
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100	100
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Income Statement [Abstract]
Revenues	$ 1,070,219	$ 1,599,147
Cost of revenues	104,313	149,120
Gross profit	965,906	1,450,027
General and administrative expenses	3,142,211	3,091,459
Loss from operations	(2,176,305)	(1,641,432)
Other income (expense)
Interest expense	(60,966)	(40,304)
Change in Commitment Fee Shortfall Obligation	(49,385)	(12,000)
Loss before taxes	(2,286,656)	(1,693,736)
Provision for income taxes
Net loss	$ (2,286,656)	$ (1,693,736)
Net loss per common share - basic and diluted	$ 0	$ 0
Weighted average number of common shares outstanding - basic and diluted	1,401,909,813	1,059,226,886

CONSOLIDATED CHANGES TO STOCKHO

CONSOLIDATED CHANGES TO STOCKHOLDER'S DEFICIT (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Oct. 31, 2021	$ 1,132,361	$ 37,826,795	$ (41,624,749)	$ (2,665,593)
Beginning balance, shares at Oct. 31, 2021	1,132,361,005
Sale of common stock	$ 8,667	411,333		420,000
Sale of common stock, shares	8,666,667
Stock-based compensation	$ 5,100	523,790		528,890
Stock based compensation, shares	5,100,000
Common stock issued as commitment fee for Promissorry Note	$ 3,077	119,923		123,000
Common stock issued as commitment fee for Promissory Note, shares	3,076,923
Net loss			(1,693,736)	(1,693,736)
Ending balance, value at Jan. 31, 2022	$ 1,149,205	38,881,841	(43,318,485)	(3,287,439)
Ending balance, shares at Jan. 31, 2022	1,149,204,595
Beginning balance, value at Oct. 31, 2022	$ 1,479,126	50,930,784	(50,521,306)	1,888,604
Beginning balance, shares at Oct. 31, 2022	1,479,126,390
Sale of common stock	$ 4,456	95,544		100,000
Sale of common stock, shares	4,456,328
Stock-based compensation	$ 5,175	969,888		975,063
Stock based compensation, shares	5,175,000
Net loss			(2,286,656)	(2,286,656)
Ending balance, value at Jan. 31, 2023	$ 1,488,757	$ 51,996,216	$ (52,807,962)	$ 677,011
Ending balance, shares at Jan. 31, 2023	1,488,757,718

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,286,656)	$ (1,693,736)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	155,800	14,170
Amortization of OID and commitment fee discount – Promissory Note	36,889	31,778
Change in Commitment Fee Shortfall Obligation	49,385	12,000
Stock-based compensation	975,063	528,890
Changes in operating assets and liabilities:
Accounts receivable	(51,785)	(9,863)
Receivables from related party	10,000
Other receivables	(567)
Prepaid expenses	(41,575)	(57,591)
Inventories	(32,834)	78,452
Accounts payable and accrued expenses	(110,175)	360,015
Accrued liabilities to management		188,066
Security deposits	9,536	(2,600)
Deferred revenue	4,195	(9,575)
Net cash used in operating activities	(1,282,724)	(559,994)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets	(16,117)	(155,134)
Net cash used in investing activities	(16,117)	(155,134)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Promissory Note		540,000
Funds held in escrow for share repurchase	(500,000)
Payments on finance lease	(31,755)	(12,122)
Repayments of notes payable	(600,000)	(171,000)
Proceeds from sale of common stock	100,000	400,000
Net cash (used in) provided by financing activities	(1,031,755)	756,878
(Decrease) increase in cash	(2,330,596)	41,750
Cash at beginning of period	3,753,097	108,570
Cash at end of period	1,422,501	150,320
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for taxes
Cash paid for interest	22,434	11,307
NON-CASH INVESTING AND FINANCING TRANSACTIONS:
OID discount on proceeds received from Promissory Note		60,000
Stock purchased from payments due on accounts payable		20,000
Common stock issued as commitment fee for Promissory Note		123,000
Commitment Fee Shortfall Obligation		77,000
Promissory note issued for past due Professional Fees		$ 256,000

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	3 Months Ended
	Jan. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Organicell Regenerative Medicine, Inc. f/k/a Biotech Products Services and Research, Inc. (“Organicell” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Our proprietary products are principally used in the health care industry administered through doctors and clinics (collectively, “Providers”). On May 21, 2018, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the Company’s name from Biotech Products Services and Research, Inc. to Organicell Regenerative Medicine, Inc., effective June 20, 2018 (the “Name Change”) and during November 2021 the Name Change was effectuated in the marketplace by the Financial Industry Regulatory Agency. For the three months ended January 31, 2023, the Company principally operated through General Surgical of Florida, Inc., a Florida corporation and wholly owned subsidiary, which was formed to sell the Company’s therapeutic products to Providers. The Company’s leading product, Zofin™ (also known as Organicell TM In June 2021, the Company announced that it was launching a service platform for its first autologous product called Patient Pure X TM TM TM TM

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities Exchange Commission, although we believe that the disclosures made are adequate to make the information not misleading. These unaudited consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended October 31, 2022 filed with the Securities and Exchange Commission. Concentrations of Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $ 250,000 1,152,448 Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Accounts Receivable Accounts receivable are recorded at net realizable value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the three months ended January 31, 2023 and 2022, the Company did no Inventory Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides reserves for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At January 31, 2023 and 2022, the Company determined that there were not any reserves required in connection with our inventory. Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 15 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Leasehold Improvements Leasehold improvements in excess of $ 1,000 1,000 Revenue Recognition The Company follows the guidance of FASB Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer. Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments. At January 31, 2023, the Company had 408,800,000 9,500,000 39,836,000 Stock-Based Compensation All stock-based payments are recognized in the financial statements based on their fair values. Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $ 194,700 276,300 Income Taxes The Company files a consolidated tax return that includes all of its subsidiaries. Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. For the three months ended January 31, 2023 and 2022 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during those periods. There is a full valuation allowance established for the tax benefit associated with the net losses for the three months ended January 31, 2023 and 2022. Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. Sequencing The Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. The Company currently has 2,500,000,000 1,490,677,642 Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company did not have any convertible instruments outstanding at January 31, 2023 and October 31, 2022 that qualify as derivatives. Operating Lease Obligations Under the provisions of Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), the Company recognizes a right of use (“ROU”) asset and corresponding lease liability for all operating leases upon commencement of the lease. The Company applies the modified retrospective approach which includes a number of optional practical expedients on leases that commenced before the effective date of ASC 842, including continuing to account for leases that commenced before the effective date in accordance with previous guidance, unless the lease is modified and the inclusion of amounts pertaining to the maintenance portion of the leased assets. The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $ 15,000 Subsequent Events The Company has evaluated subsequent events that occurred after January 31, 2023 through the financial statement issuance date for subsequent event disclosure consideration.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Jan. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN The accompanying unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has had limited revenues since its inception. The Company incurred net losses of $ 2,176,305 52,807,962 773,385 United States Food and Drug Administration (“FDA”) regulations which were announced in November 2017 and which became effective beginning in May 2021 (postponed from November 2020 due to the COVID-19 pandemic) require that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products (“HCT/Ps”) can only be sold pursuant to an approved biologics license application (“BLA”). The Company has not obtained any opinion or ruling regarding the Company’s operations and whether the processing, sales and distribution of the products it currently produces would be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s. In addition to the above, the adverse public health developments associated with the ongoing COVID-19 pandemic combined with the downturn in the overall United States and global economies have adversely affected the demand for our products and services by our customers and from patients of our customers and which currently still continue to have a negative impact to our business and the economy. As a result of the above, the Company’s efforts to establish a stabilized source of sufficient revenues to cover operating costs has yet to be achieved and ultimately may prove to be unsuccessful unless (a) the Company’s ability to process, sell and distribute the products currently being produced or developed in the future are not restricted; (b) the United States economy returns to pre-COVID-19 conditions; and/or (c) additional sources of working capital through operations or debt and/or equity financings are realized. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products. The Company does not have any assets to pledge for the purpose of borrowing additional capital. In addition, the Company relies on its ability to produce and sell products it manufactures that are subject to changing technology and regulations that it currently sells and distributes to its customers. The Company’s current market capitalization, common stock liquidity and available authorized shares may hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive, if available at all. In view of the matters described in the preceding paragraphs, recoverability of the recorded asset amounts shown in the accompanying consolidated balance sheet assumes that (a) the Company is able to continue to produce products or obtain products under supply arrangements which are in compliance with current and future regulatory guidelines; (b) the United States economy returns to pre-COVID-19 market conditions; (c) the Company will be able to establish a stabilized source of revenues, including efforts to expand sales internationally and the development of new product offerings and/or designations of products; (d) obligations to the Company’s creditors are not accelerated; (e) the Company’s operating expenses remain at current levels and/or the Company is successful in restructuring and/or deferring ongoing obligations; (f) the Company is able to continue its research and development activities, particularly in regards to remaining compliant with the FDA and ongoing safety and efficacy of its products; and/or (g) the Company obtains additional working capital to meet its contractual commitments and maintain the current level of Company operations through debt or equity sources. There is no assurance that the products we currently produce will not be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s and/or the Company will be able to complete its revenue growth strategy. There is no assurance that the Company’s research and development activities will be successful or that the Company will be able to timely fund the required costs of those activities. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversely impacted. Furthermore, despite significant effort since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues. If revenues do not increase and stabilize, if the Company’s ability to process, sell and/or distribute the products currently being produced or developed in the future are restricted, and/or if additional funds cannot otherwise be raised, the Company might be required to seek other alternatives which could include the sale of assets, closure of operations and/or protection under the U.S. bankruptcy laws. As of January 31, 2023, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.

INVENTORIES

INVENTORIES	3 Months Ended
	Jan. 31, 2023
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4 – INVENTORIES Schedule of Inventories January 31, October 31, Raw materials and supplies $ 69,703 $ 85,096 Finished goods 211,641 163,414 Total inventories $ 281,344 $ 248,510

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Jan. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 5 – PROPERTY AND EQUIPMENT Schedule of Property and Equipment January 31, October 31, Computer equipment $ 29,021 $ 26,881 Finance lease equipment 544,378 544,378 Manufacturing equipment 639,956 625,979 Leasehold improvements 925,932 925,932 2,139,287 2,123,170 Less: accumulated depreciation and amortization (595,454 ) (439,654 ) Total property and equipment, net $ 1,543,833 $ 1,683,516 Depreciation expense totaled $ 29,143 14,170 As described in Note 6, during the year ended October 31, 2021, the Company began the build-out of additional laboratory processing, product distribution and administrative office capacity at its Basalt Lab Lease location. The Basalt Lab Lease location became operational during May 2022 and amortization of these costs began during May 2022. Amortization expense totaled $ 126,657 0

LEASE OBLIGATIONS

LEASE OBLIGATIONS	3 Months Ended
	Jan. 31, 2023
Leases [Abstract]
LEASE OBLIGATIONS	NOTE 6 – LEASE OBLIGATIONS Finance Lease Obligations: During March 2019, the Company entered into a lease agreement for certain lab equipment in the amount of $ 239,595 4,513 1.00 4.5 15 During October 2021, the Company entered into a second lease agreement in the amount of $ 304,873 5,478 1.00 3.0 15 Operating Lease Obligations: On August 30, 2022, the Company entered into a one-year lease agreement (“LA Office Lease”) for office space in Los Angeles, California commencing September 1, 2022 and ending August 31, 2023. The Company was required to make a one-time prepayment of the annual rent in the amount of $ 160,000 10,000 Laboratory Facilities: Effective July 1, 2022, the Company entered into a six-month lease agreement for an approximately 450 square foot laboratory and additional administrative office space effective July 1, 2022 (“New Miami Lab Lease”). Monthly lease payments are approximately $ 9,500 6,332 Effective October 10, 2022, the Company relocated its Miami laboratory to a 1,156 square foot administrative and laboratory facility at the Nova Southeastern University Center for Collaborative Research in Davie, Florida. This space is occupied pursuant to one year license agreement (“University Lease”) for an annual base license fee of $ 20,230 During March 2021, the Company entered into a lease agreement for an approximately 2,452 square foot commercial space located in Basalt, Colorado (the “Basalt Lab Lease”). The Company intends to build additional laboratory processing, product distribution and administrative office capacity from this location. The term of the Basalt Lab Lease is for three years and may be renewed for an additional (3) three-year term provided the Company is not in default (“First Renewal Option”). Rental expense is $ 6,800 13,600 925,932 In connection with the execution of the Basalt Lab Lease, the Company recorded a ROU asset and corresponding operating lease obligation of $ 235,313 4.5 Lease amortization expense for the three months ended January 31, 2023 and 2022 was $ 19,838 18,361

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Jan. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7 – RELATED PARTY TRANSACTIONS For the three months ended January 31, 2023 and 2022, the Company sold a total of approximately $ 25,230 79,700

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Jan. 31, 2023
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 8 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Schedule of account payable and accrued expenses January 31, October 31, Accrued payroll related liabilities $ 666,780 $ 666,780 Lab equipment and supplies payables 463,123 477,255 Clinical trial payables 462,927 312,711 Legal fees payables 204,049 328,121 Other professional fees payables 153,177 90,993 Accrued IRS penalty 83,684 83,684 Accrued commissions payable 29,628 39,675 Construction payables 9,317 5,474 Other payables and accrued expenses 195,671 373,838 Accounts Payable and Accrued Expenses $ 2,268,356 $ 2,378,531

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Jan. 31, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 9 – NOTES PAYABLE Promissory Note – SPA 22 On January 11, 2022, the Company entered into a Securities Purchase Agreement (“SPA 22”) with AJB Capital Investments, LLC (“Purchaser”) pursuant to which we sold a promissory note in the principal amount of $ 600,000 60,000 January 11, 2023 Pursuant to the terms of the SPA 22, the Company paid a commitment fee to the Purchaser in the amount of $ 123,000 3,076,923 0.04 33,231 1,538,462 0.0216 In the event that by the earlier of the first anniversary of repayment of the Promissory Note by the Company or the date that the Purchaser has sold all of the Commitment Fee Shares (“True-Up Date”), the Purchaser has not generated the amount of $ 300,000 Upon the closing, the Company recorded a discount of the Promissory Note in the amount of $ 260,000 60,000 123,000 77,000 100,000 66,769 For the three months ended January 31, 2023 and 2022, $ 36,889 31,778 At January 31, 2023 and 2022, the fair value of the Commitment Fee Shares was approximately $223,846 (valued at $0.0165 the closing price of the common stock of the Company on January 31, 2023) and approximately $111,000 (valued at $0.036 the closing price of the common stock of the Company on January 31, 2022), respectively. As a result, the Company has recorded an increase in the Commitment Fee Shortfall Obligation in the amount of $ 49,385 12,000 223,847 89,000 On February 10, 2023, the Company received a notice from the Purchaser that it had sold all of the Commitment Fee Shares and that the Commitment Fee Shortfall Obligation of $ 187,519 36,327 11,719,925 0.016 Promissory Note – SPA 23 On March 6, 2023, the Company entered into another Securities Purchase Agreement (“SPA 23”) with the Purchaser, pursuant to which we sold a promissory note in the principal amount of $ 530,000 10,600 15,000 504,400 The Note matures on September 6, 2023, bears interest at the rate of 12 120,000,000 The Note may be prepaid by the Company at any time without penalty. The Note also contains covenants, events of defaults, penalties, default interest and other terms and conditions customary in transactions of this nature. Pursuant to the terms of the SPA 23, the Company paid a commitment fee to the Purchaser in the amount of $ 300,000 15,000,000 10,000,000 0.06 Pursuant to the terms of the SPA 23, the Company granted certain piggyback registration rights under the Securities Act of 1933, as amended, with respect to the Conversion Shares, the Warrant Shares and the Commitment Fee Shares.

IRS PENALTIES

IRS PENALTIES	3 Months Ended
	Jan. 31, 2023
Irs Penalties
IRS PENALTIES	NOTE 10 – IRS PENALTIES The Company’s income tax returns for the periods since inception through the tax year ended October 31, 2015 were not filed with the Internal Revenue Service (“IRS”) until August 2017 (“Delinquent Filed Returns”). The Company’s income tax returns for the tax year ended October 31, 2016 were filed with the IRS during December 2017. In connection with the Delinquent Filed Returns, during the period September 2017 through October 2017, the Company received notices that it was being assessed approximately $ 90,000 20,000 83,684 83,684

CAPITAL STOCK

CAPITAL STOCK	3 Months Ended
	Jan. 31, 2023
Equity [Abstract]
CAPITAL STOCK	NOTE 11 – CAPITAL STOCK Common Stock Issuances of Common Stock – Stock-Based Compensation: On December 1, 2022, the Company granted 150,000 0.03 4,500 On December 29, 2022, the Company agreed to issue 5,000,000 100,000 0.02 100,000 Equity Line of Credit Commitment: During November 2021, the Company entered into an term sheet agreement with Tysadco Partners LLC, a Delaware limited company (“Tysadco”) whereby Tysadco agreed to provide the Company with a $ 10,000,000 On September 1, 2022, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with Tysadco and a Registration Rights Agreement (the “Registration Rights Agreement”) with Tysadco. Pursuant to the Purchase Agreement, Tysadco committed to purchase, subject to certain restrictions and conditions, up to $10,000,000 worth of the Company’s common stock (the “Commitment”), over a period of 24 months from the effectiveness of the registration statement registering the resale of shares purchased by Tysadco pursuant to the Purchase Agreement (the “Registration Statement”). Pursuant to the terms of the Registration Rights Agreement, the Company was obligated to use its commercially reasonable efforts to file a registration statement with the Securities and Exchange Commission within thirty (30) days after the date of such agreement, to register the resale by Tysadco of the shares of common stock issuable under the Purchase Agreement. On September 2, 2022, the Company filed the required registration statement and on October 24, 2022, the Registration Statement was declared effective. The Purchase Agreement provides that at any time after the effective date of the Registration Statement, from time to time on any business day selected by the Company (the “Purchase Date”), the Company shall have the right, but not the obligation, to direct Tysadco to buy the lesser of $1,000,000 in common stock per sale or 500% of the daily average share value traded for the 10 days prior to the closing request date, at a purchase price of 80% of the of the two lowest individual daily VWAPs during the ten (10) trading days preceding the draw down or put notice (“Valuation Period”), with a minimum request of $25,000 (“Request”). The payment for the shares covered by each request notice will occur on the business day immediately following the Valuation Period. In addition, Tysadco will not be obligated to purchase shares if Tysadco’s total number of shares beneficially held at that time would exceed 9.99% of the number of shares of the Company’s common stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, the Company is not permitted to draw on the Purchase Agreement unless the Registration Statement covering the resale of the shares is effective. The Purchase Agreement also contains customary representations and warranties of each of the parties. The assertions embodied in those representations and warranties were made for purposes of the Purchase Agreement and are subject to qualifications and limitations agreed to by the parties in connection with negotiating the terms of the Purchase Agreement. The Purchase Agreement further provides that the Company and Tysadco are each entitled to customary indemnification from the other for, among other things, any losses or liabilities they may suffer as a result of any breach by the other party of any provisions of the Purchase Agreement or Registration Rights Agreement. The Company has the unconditional right, at any time, for any reason and without any payment or liability, to terminate the Purchase Agreement. Pursuant to the Purchase Agreement, on December 2, 2022, the Company submitted a put request to Tysadco to purchase 4,456,326 registered shares at a purchase price of $0.02244, for a total of $100,000 (“Put Request”). On December 5, 2022, Tysadco funded the Put Request and the Company issued 4,456,326 shares to Tysadco. The proceeds from the share sale are being used for working capital and general corporate purposes. Shares Repurchased – Settlement of Litigation: As described in Note 13, effective October 13, 2022, the Company settled a lawsuit by agreeing to repurchase 24,800,001 500,000 Unvested Equity Instruments A summary of unvested equity instruments outstanding for the three months ended January 31, 2023 and 2022 are presented below: Schedule of Nonvested Share Activity Number of Weighted- Outstanding at October 31, 2022 99,843,151 $ 0.057 Non-Vested Shares Granted - $ - Vested (13,996,575 ) $ 0.061 Expired/Forfeited (15,846,576 ) $ 0.034 Outstanding at January 31, 2023 70,000,000 $ 0.069 Number of Weighted- Outstanding at October 31, 2021 83,844,445 $ 0.062 Non-Vested Shares Granted 1,900,000 $ 0.034 Vested (166,667 ) $ 0.029 Expired/Forfeited - $ - Outstanding at January 31, 2022 85,577,778 $ 0.061

WARRANTS

WARRANTS	3 Months Ended
	Jan. 31, 2023
Warrants
WARRANTS	NOTE 12 – WARRANTS A summary of warrant activity for the three months ended January 31, 2023 and 2022 are presented below: Summary of Warrant Activity Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2022 429,800,000 $ 0.02 9.63 $ 2,440,110 Granted - $ - - $ - Exercised - $ - - $ - Expired/Forfeited (21,000,000 ) $ 0.03 9.51 $ - Outstanding at January 31, 2023 408,800,000 $ 0.02 9.38 $ - Exercisable at January 31, 2023 392,645,434 $ 0.02 9.37 $ - Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2021 9,500,000 $ 0.03 6.90 $ 289,500 Granted - $ - - $ - Exercised - $ - - $ - Expired/Forfeited - $ - - $ - Outstanding and exercisable at January 31, 2022 9,500,000 $ 0.03 6.65 $ 62,250

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 – COMMITMENTS AND CONTINGENCIES Executive Employment Agreements The Company is party to executive employment agreements with each of Ian T. Bothwell (our Interim Chief Executive Officer and Chief Financial Officer), Dr. Maria Ines Mitrani (our Chief Science Officer) and Albert Mitrani, our Executive Vice President of Sales), originally executed in April 2018 and subsequently amended (the “ Executive Employment Agreements 300,000 Pursuant to the terms of the SPA, the Executive Employment Agreements were further amended on August 19, 2022 and February 9, 2023 as follows: 1. Each of Albert Mitrani, Dr. Maria Ines Mitrani and Ian Bothwell amended their respective employment agreements providing for (a) setting their respective base salaries at $ 300,000 In addition, each of Albert Mitrani, Dr. Maria Ines Mitrani and Ian Bothwell agreed to a reduction in each executive’s annual salary to $ 150,000 2. Albert Mitrani and Dr. Maria Ines Mitrani each waived all accrued but unpaid compensation outstanding as of July 31, 2022. The Company, Albert Mitrani and Dr. Maria Ines Mitrani also agreed to terminate the leases with Mariluna LLC for use of Albert Mitrani’s and Mari Mitrani’s Miami, FL and Aspen, Colorado homes, retroactive to July 13, 2022. The Company wrote off the related ROU asset and lease liability as of the Closing Date. The balance of unpaid and accrued compensation that was forgiven by Albert Mitrani and Dr. Maria Ines Mitrani totaling $ 430,200 563,455 3. Ian Bothwell waived all unpaid and accrued compensation outstanding as of July 31, 2022, in exchange for ten-year warrants to purchase 30,000,000 0.02 455,478 4. Each of Albert Mitrani, Dr. Maria Ines Mitrani, Ian Bothwell and all other recipients agreed to terminate all awards granted but not yet issued under the Company’s Management and Consultant Performance Plan. 5. Each of Albert Mitrani, Dr. Maria Ines Mitrani and Ian Bothwell agreed to modify severance compensation provisions to be paid upon termination to only occur upon a termination without cause in an amount equal to one month’s base salary for each year of service. In connection with the February 9, 2023 amendment to the Executive Employment Agreements, Mr. Bothwell and Mr. Mitrani also agreed to repay approximately $ 44,600 84,300 44,600 74,300 Term Sheet – Acting CEO On July 21, 2022 (“Effective Date”), Matthew Sinnreich was appointed by the Board of Directors to the position of Chief Operating Officer and Acting Chief Executive Officer. On the Effective Date, Organicell and Mr. Sinnreich entered into a term sheet (the “Term Sheet”) setting forth in principle the terms of Mr. Sinnreich’s employment agreement with and compensation by the Company. The Term Sheet was subject to the negotiation and execution of a definitive employment agreement embodying the provisions of the Term Sheet, as well as customary terms and conditions for an executive employment agreement (the “Employment Agreement”). The parties agreed to use their respective commercial best efforts to negotiate and execute the Employment Agreement. In connection with the Term Sheet, as an inducement for Mr. Sinnreich to join the Company, Mr. Sinnreich was issued 10,000,000 40,000,000 0.034 During the first year of the Initial Term, Mr. Sinnreich was to be compensated by the issuance of 24,000,000 25,000 On September 13, 2022, Mr. Sinnreich assumed the position of President and Acting Chief Executive Officer. He subsequently resigned from the Company on November 22, 2022. During the period November 1, 2022 through November 22, 2022 and as of November 22, 2022, a total of 1,446,575 Consultant Agreements Assure Immune LLC On August 19, 2022 the Company and Consultant agreed to an amendment to the consulting agreement whereby the Consultant was issued 5,000,000 shares of common stock of the Company and received a $20,000 cash payment in exchange for satisfaction of approximately $200,000 in outstanding consulting fees due to the Consultant up through August 31, 2022. The parties also agreed to the reduction of future fees payable to the Consultant from $40,000 per month to $15,000 per month for the period September 2022 through March 2023. Preparation of IRB, Pre-IND, IND Protocols for Clinical Applications and Clinical Trial Initiation and Monitoring In connection with the Company’s ongoing research and development efforts and the Company’s efforts to meet compliance with current and anticipated United States Food and Drug Administration (“FDA”) regulations expected to be enforced beginning in May 2021 pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products that fall under Section 351 of the Public Health Services Act (“HCT/Ps”), the Company has applied for and received Investigation New Drug (“IND”) approval from the FDA to commence clinical trials in connection with the use of the Company’s products and related treatment protocols for specific indications. The ability to successfully complete the above efforts will be dependent on the actual outcomes in connection with the use of the Company’s products and related treatment protocols for each clinical trial, the Company’s ability to timely enroll patients and fund the required payments and complete the applicable clinical trials, which is subject to available working capital generated from operations, financing arrangements with the third-party vendors involved in the studies and/or from additional debt and/or equity financings as well as the ultimate approval from the FDA. New CRO Agreements During August 2021, October 2021, and December 2021, the Company entered into agreements with a new CRO to provide ongoing clinical research and related services in connection with two of the Company’s approved clinical research trials (“New CRO Agreements”). On August 23, 2022 the New CRO Agreements were amended. In connection with the New CRO Agreements, the Company is obligated to make aggregate payments to the CRO of approximately $1,443,000 plus estimated aggregate pass-through costs and other third-party direct costs of approximately $495,000 (“Pass-Through Costs”) as well as site and patient related costs. The Company is obligated to make the CRO payments based on the actual costs incurred over the term of the clinical trial beginning on the commencement of the work by the CRO in connection with the applicable clinical trial and the payments for the pass-through costs and other third-party direct costs as well as site and patient related costs are paid in accordance with completion of agreed upon milestones. As of January 31, 2023, the Company has been billed a total of approximately $617,100 and $176,200, in connection with the New CRO Agreements and Pass-Through Costs, respectively, of which approximately $ 303,800 Legal Matters SEC Matter On June 17, 2021, Organicell received a subpoena dated June 14, 2021, from the Atlanta Regional Office of the SEC requiring the production of certain documents and communications in connection with the treatment and results of various COVID-19 patients, as discussed in the Company’s Current Reports on Form 8-K filed with the SEC during the period from May 27, 2020 through May 11, 2021. The Company is fully cooperating with the SEC’s investigation and believes that it will be able to provide all of the information requested by the SEC. The Company can make no assurances as to the time or resources that will need to be devoted to this investigation or its final outcome, or the impact, if any, of this investigation or any proceedings on the Company’s current business, financial condition, results of operations, cash flows, or the Company’s future operations. Daniel Pepock and Tracy Yourke The Company terminated the employment agreements with the Sales Executives Daniel Pepock (“Pepock”) and Tracy Yourke (“Yourke”) effective June 30, 2022. On June 6, 2022, Pepock filed a Complaint against Organicell Regenerative Medicine, Inc. (“Organicell”) in the Court of Common Pleas of Westmoreland County, Pennsylvania. Organicell removed the case to the United States District Court for the Western District of Pennsylvania, and on July 15, 2022 Mr. Pepock filed an Amended Complaint asserting two counts. On June 27, 2022, Ms. Yourke filed a complaint against Organicell in the State of Michigan, 6 th As of July 31, 2022, all past due wages to Pepock and Yourke were paid. Mr. Pepock’s action against Organicell was designated for placement into the United States District Court’s Alternative Dispute Resolution program and the Parties agreed to mediate. On August 22, 2022, Mr. Pepock, Ms. Yourke and Organicell agreed to a material settlement term sheet (“Settlement”) which provided for the resolution and full settlement and release of all claims among the parties and for the Company to buy back all of the shares of common stock of the Company issued to and owned by Mr. Pepock and Ms. Yourke at the time of the Settlement (represented by Mr. Pepock and Ms. Yourke to be in excess of 24,800,000 shares) in exchange for a payment by the Company of $500,000 (“Purchase Price”). In addition, the Company agreed to release Mr. Pepock and Ms. Yourke from their non-compete restrictions upon transfer of the shares to the Company. The Settlement relates to disputed claims and nothing therein shall be construed as an admission of liability or wrongdoing by the Company or any other party. Effective October 13, 2022, the parties executed a Confidential Settlement Agreement and Mutual General Release memorializing the terms of the Settlement. Under the terms of the Settlement, the Company agreed to repurchase 24,800,001 500,000 500,000 The shares repurchased were transferred to the Company on February 2. 2023 and the escrow funds were released. The shares repurchased were redeposited back into the Company’s treasury of authorized and unissued shares on February 3, 2023. As a result of the above, the matter has been fully settled and Mr. Pepock and Ms. Yourke were released from their non-compete restrictions. Other In addition to the foregoing, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm our business.

401(K) PLAN

401(K) PLAN	3 Months Ended
	Jan. 31, 2023
K Plan
401(K) PLAN	NOTE 14 – 401(K) PLAN The Company sponsors a pooled defined contribution retirement plan (“401(k) Plan”) covering all eligible employees effective January 25, 2023. The 401(k) Plan allows eligible employees to contribute, subject to Internal Revenue Service limitations on total annual contributions, up to 92% of their compensation as defined in the 401(k) Plan, to various investment funds. Under the 401(k) Plan, the Company may, but is not obligated to, make any contributions to the 401(K) Plan for any eligible employees. The Company has no

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Jan. 31, 2023
Segment Reporting [Abstract]
SEGMENT INFORMATION	NOTE 15 – SEGMENT INFORMATION The Company has only one operating segment.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities Exchange Commission, although we believe that the disclosures made are adequate to make the information not misleading. These unaudited consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended October 31, 2022 filed with the Securities and Exchange Commission.
Concentrations of Credit Risk	Concentrations of Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $ 250,000 1,152,448
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at net realizable value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the three months ended January 31, 2023 and 2022, the Company did no
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides reserves for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At January 31, 2023 and 2022, the Company determined that there were not any reserves required in connection with our inventory.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 15 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.
Leasehold Improvements	Leasehold Improvements Leasehold improvements in excess of $ 1,000 1,000
Revenue Recognition	Revenue Recognition The Company follows the guidance of FASB Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments. At January 31, 2023, the Company had 408,800,000 9,500,000 39,836,000
Stock-Based Compensation	Stock-Based Compensation All stock-based payments are recognized in the financial statements based on their fair values.
Research and Development Costs	Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $ 194,700 276,300
Income Taxes	Income Taxes The Company files a consolidated tax return that includes all of its subsidiaries. Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. For the three months ended January 31, 2023 and 2022 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during those periods. There is a full valuation allowance established for the tax benefit associated with the net losses for the three months ended January 31, 2023 and 2022.
Valuation of Derivatives	Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date.
Sequencing	Sequencing The Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. The Company currently has 2,500,000,000 1,490,677,642
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company did not have any convertible instruments outstanding at January 31, 2023 and October 31, 2022 that qualify as derivatives.
Operating Lease Obligations	Operating Lease Obligations Under the provisions of Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), the Company recognizes a right of use (“ROU”) asset and corresponding lease liability for all operating leases upon commencement of the lease. The Company applies the modified retrospective approach which includes a number of optional practical expedients on leases that commenced before the effective date of ASC 842, including continuing to account for leases that commenced before the effective date in accordance with previous guidance, unless the lease is modified and the inclusion of amounts pertaining to the maintenance portion of the leased assets. The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $ 15,000
Subsequent Events	Subsequent Events The Company has evaluated subsequent events that occurred after January 31, 2023 through the financial statement issuance date for subsequent event disclosure consideration.

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Jan. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventories	Schedule of Inventories January 31, October 31, Raw materials and supplies $ 69,703 $ 85,096 Finished goods 211,641 163,414 Total inventories $ 281,344 $ 248,510

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Jan. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment January 31, October 31, Computer equipment $ 29,021 $ 26,881 Finance lease equipment 544,378 544,378 Manufacturing equipment 639,956 625,979 Leasehold improvements 925,932 925,932 2,139,287 2,123,170 Less: accumulated depreciation and amortization (595,454 ) (439,654 ) Total property and equipment, net $ 1,543,833 $ 1,683,516

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Jan. 31, 2023
Payables and Accruals [Abstract]
Schedule of account payable and accrued expenses	Schedule of account payable and accrued expenses January 31, October 31, Accrued payroll related liabilities $ 666,780 $ 666,780 Lab equipment and supplies payables 463,123 477,255 Clinical trial payables 462,927 312,711 Legal fees payables 204,049 328,121 Other professional fees payables 153,177 90,993 Accrued IRS penalty 83,684 83,684 Accrued commissions payable 29,628 39,675 Construction payables 9,317 5,474 Other payables and accrued expenses 195,671 373,838 Accounts Payable and Accrued Expenses $ 2,268,356 $ 2,378,531

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	3 Months Ended
	Jan. 31, 2023
Equity [Abstract]
Schedule of Nonvested Share Activity	Schedule of Nonvested Share Activity Number of Weighted- Outstanding at October 31, 2022 99,843,151 $ 0.057 Non-Vested Shares Granted - $ - Vested (13,996,575 ) $ 0.061 Expired/Forfeited (15,846,576 ) $ 0.034 Outstanding at January 31, 2023 70,000,000 $ 0.069 Number of Weighted- Outstanding at October 31, 2021 83,844,445 $ 0.062 Non-Vested Shares Granted 1,900,000 $ 0.034 Vested (166,667 ) $ 0.029 Expired/Forfeited - $ - Outstanding at January 31, 2022 85,577,778 $ 0.061

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Jan. 31, 2023
Warrants
Summary of Warrant Activity	Summary of Warrant Activity Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2022 429,800,000 $ 0.02 9.63 $ 2,440,110 Granted - $ - - $ - Exercised - $ - - $ - Expired/Forfeited (21,000,000 ) $ 0.03 9.51 $ - Outstanding at January 31, 2023 408,800,000 $ 0.02 9.38 $ - Exercisable at January 31, 2023 392,645,434 $ 0.02 9.37 $ - Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2021 9,500,000 $ 0.03 6.90 $ 289,500 Granted - $ - - $ - Exercised - $ - - $ - Expired/Forfeited - $ - - $ - Outstanding and exercisable at January 31, 2022 9,500,000 $ 0.03 6.65 $ 62,250

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Oct. 31, 2022	Mar. 16, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
FDIC limits per institutions	$ 250,000
Cash Balances	1,152,448
Bad debt expense	0	$ 0
Leasehold improvements	1,000
Incremental salary		39,836,000
Research and Development Expense	$ 194,700	$ 276,300
Common stock, shares authorized	2,500,000,000		2,500,000,000	2,500,000,000
Common stock, shares issued	1,488,757,718		1,479,126,390	1,490,677,642
Operating and finance lease obligation	$ 15,000
Common Shares Issuable Upon Exercise Of Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	408,800,000	9,500,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Oct. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Loss from operations	$ 2,176,305	$ 1,641,432
Accumulated deficit	52,807,962		$ 50,521,306
Working capital deficit	$ 773,385

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Jan. 31, 2023	Oct. 31, 2022
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 69,703	$ 85,096
Finished goods	211,641	163,414
Total inventories	$ 281,344	$ 248,510

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jan. 31, 2023	Oct. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,139,287	$ 2,123,170
Less: accumulated depreciation and amortization	(595,454)	(439,654)
Total property and equipment, net	1,543,833	1,683,516
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	29,021	26,881
Finance lease equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	544,378	544,378
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	639,956	625,979
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 925,932	$ 925,932

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 29,143	$ 14,170
Amortization expense	$ 126,657	$ 0

LEASE OBLIGATIONS (Details Narr

LEASE OBLIGATIONS (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended		5 Months Ended
	Oct. 10, 2022	Aug. 30, 2022	Mar. 31, 2021	Jan. 31, 2023	Jan. 31, 2022	Mar. 31, 2019	Oct. 31, 2022	Jul. 02, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Monthly payments				$ 5,478
Operating leased equipment, per unit				1
Security deposit				$ 30,400			$ 39,936
Basalt Lab Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expense			$ 6,800
Operating lease obligation			$ 235,313
Borrowing rate			4.50%
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment to acquire						$ 239,595
Monthly payments						$ 4,513
Operating leased equipment, per unit						1
Annual interest rate				3%		4.50%
Estimated useful lives of leased equipment				15 years		15 years
Annual rent		$ 160,000
Security deposit		$ 10,000
Basalt Lab Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment to acquire			$ 925,932	$ 304,873
Lease expense				$ 19,838	$ 18,361
Miami Lab Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Security deposit								$ 6,332
Minimum monthly lease payments								$ 9,500
Annual base license fee	$ 20,230
Second Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Security deposit			$ 13,600

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Management Services Organization [Member]
Proceed from sale of products	$ 25,230	$ 79,700

AccountPayableAndAccruedExpense

AccountPayableAndAccruedExpenses (Details) - USD ($)	Jan. 31, 2023	Oct. 31, 2022
Payables and Accruals [Abstract]
Accrued payroll related liabilities	$ 666,780	$ 666,780
Lab equipment and supplies payables	463,123	477,255
Clinical trial payables	462,927	312,711
Legal fees payables	204,049	328,121
Other professional fees payables	153,177	90,993
Accrued IRS penalty	83,684	83,684
Accrued commissions payable	29,628	39,675
Construction payables	9,317	5,474
Other payables and accrued expenses	195,671	373,838
Accounts Payable and Accrued Expenses	$ 2,268,356	$ 2,378,531

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)			3 Months Ended
	Mar. 06, 2023	Jan. 11, 2022	Jan. 31, 2023	Jan. 31, 2022	Feb. 10, 2023	Oct. 31, 2022	Jul. 12, 2022
Debt Instrument [Line Items]
Maturity date		Jan. 11, 2023
Repayment of promissory note			$ 300,000
Promissory note discount						$ 563,111
Common stock issued as commitment fee for Promissory Note			123,000
Commitment Fee Shortfall Obligation			77,000
Commitmnet shortfaal obligation			49,385	$ 12,000
Commitment fee discount			36,889	31,778
Commitment fee shortfall obligation			223,847	89,000	$ 187,519	$ 174,462
Commitment Fee			$ 36,327
Conversion of stock, shares issued			11,719,925
Conversion price					$ 0.016
Legal fees	$ 15,000
Proceeds from note payble	504,400
Interest rate			12%
Number of shares reserved			120,000,000
Promissory Note [Member]
Debt Instrument [Line Items]
Discount			$ 60,000
Promissory note discount			260,000				$ 100,000
Commitmnet shortfaal obligation			$ 66,769
Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principal amount	530,000	$ 600,000
Discount	$ 10,600	$ 60,000
Commitment fee				$ 123,000
Number of shares issued			3,076,923
Share price			$ 0.04
Securities Purchase Agreement [Member] | Additional Commitment [Member]
Debt Instrument [Line Items]
Commitment fee			$ 33,231
Number of shares issued			1,538,462
Share price			$ 0.0216
Securities Purchase Agreement 1 [Member]
Debt Instrument [Line Items]
Commitment fee			$ 300,000
Number of shares issued			15,000,000
Share price			$ 0.06
Securities Purchase Agreement 1 [Member] | Additional Commitment [Member]
Debt Instrument [Line Items]
Number of shares issued			10,000,000

IRS PENALTIES (Details Narrativ

IRS PENALTIES (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2011	Oct. 31, 2022
Irs Penalties
Penalties	$ 90,000	$ 20,000
Accrued tax penalties	$ 83,684		$ 83,684

CAPITAL STOCK (Details - Unvest

CAPITAL STOCK (Details - Unvested equity instruments) - $ / shares	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Equity [Abstract]
Number of Nonvested Shares, Outstanding at beginning	99,843,151	83,844,445
Weighted-Average Grant Date Value, Outstanding at beginning	$ 0.057	$ 0.062
Number of Non-Vested Shares, Granted		1,900,000
Weighted-Average Grant Date Value, Granted		$ 0.034
Number of Non-Vested Shares, Vested	(13,996,575)	(166,667)
Weighted-Average Grant Date Value, Vested	$ 0.061	$ 0.029
Number of Non-Vested Shares, Expired/Forfeited	(15,846,576)
Weighted-Average Grant Date Value, Expired/Forfeited	$ 0.034
Number of Nonvested Shares, Outstanding at ending	70,000,000	85,577,778
Weighted-Average Grant Date Value, Outstanding at ending	$ 0.069	$ 0.061
Number of Non-Vested Shares, Expired/Forfeited	15,846,576

CAPITAL STOCK (Details Narrativ

CAPITAL STOCK (Details Narrative) - USD ($)			1 Months Ended		3 Months Ended
	Dec. 01, 2022	Oct. 13, 2022	Dec. 29, 2022	Oct. 31, 2022	Jan. 31, 2023	Jan. 31, 2022	Nov. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share-Based Payment Arrangement, Noncash Expense					$ 975,063	$ 528,890
Stock granted of period value					100,000
Cash provided for credit facility							$ 10,000,000
Number of common stock repurchase				24,800,001
Repurchase value		500,000
Employee [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares granted	150,000
Share Price	$ 0.03
Share-Based Payment Arrangement, Noncash Expense					$ 4,500
Service Provider [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares granted			5,000,000
Share Price			$ 0.02
Stock granted of period value			$ 100,000

WARRANTS (Details - Warrant Act

WARRANTS (Details - Warrant Activity) - Warrant [Member] - USD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Oct. 31, 2023
Number of Shares Outstanding beginning balance	429,800,000	9,500,000
Weighted-average Exercise Price Outstanding beginning balance	$ 0.02	$ 0.03
Remaining Contractual Term (years) Outstanding beginning balance	9 years 7 months 17 days	6 years 10 months 24 days
Aggregate Intrinsic Value Outstanding beginning balance	$ 2,440,110	$ 289,500
Number of Shares, Granted
Weighted-average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Shares, Exercised
Weighted-average Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised
Number of Shares, Expired/Forfeited	(21,000,000)
Weighted-average Exercise Price, Expired/Forfeited	$ 0.03
Remaining Contractual Term (years), expired/forfeited	9 years 6 months 3 days
Aggregate Intrinsic Value, Expired/Forfeited
Number of Shares Outstanding ending balance	408,800,000	9,500,000
Weighted-average Exercise Price Outstanding ending balance	$ 0.02	$ 0.03
Remaining Contractual Term (years) Outstanding ending balance	9 years 4 months 17 days	6 years 7 months 24 days
Aggregate Intrinsic Value Outstanding ending balance		$ 62,250
Number of Shares Exercisable	392,645,434
Weighted-average Exercise Price Exercisable	$ 0.02
Remaining Contractual Term (years) Outstanding, exercisable	9 years 4 months 13 days
Aggregate Intrinsic Value Exercisable
Number of Shares, Expired/Forfeited	21,000,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			1 Months Ended			3 Months Ended	12 Months Ended
	Feb. 09, 2023	Oct. 13, 2022	Nov. 22, 2022	Aug. 19, 2022	Jul. 21, 2022	Jan. 31, 2023	Oct. 31, 2022	Nov. 30, 2022	Apr. 30, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Vested shares			1,446,575
Contract research organization outstanding						$ 303,800
Repurchased shares		24,800,001
Repurchased shares, value		$ 500,000
Escrow account						500,000
Ian Bothwell [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unpaid and accrued compensation forgiven							$ 455,478
Number of warrants purchased							30,000,000
Exercise Price							$ 0.02
Sinnreich [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Base salary						$ 25,000
Number of restricted shares issued						10,000,000
Number of shares issued for compensation						24,000,000
Sinnreich [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrants purchased					40,000,000
Exercise Price					$ 0.034
Executive Employment Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Annual salary									$ 300,000
Executive Employment Agreements [Member] | Ian Bothwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Annual salary								$ 150,000
Base salary				$ 300,000
Reimbursed expenses	$ 44,600
Accounts receivable, related parties						$ 44,600
Executive Employment Agreements [Member] | Albert Mitrani [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unpaid and accrued compensation forgiven							$ 430,200
Executive Employment Agreements [Member] | Dr Maria Ines Mitrani [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unpaid and accrued compensation forgiven							$ 563,455
Executive Employment Agreements [Member] | Mr. Mitrani [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reimbursed expenses	$ 84,300
Accounts receivable, related parties						$ 74,300
Consultant Agreements [Member] | Assure Immune [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Consultant agreements,description				Company and Consultant agreed to an amendment to the consulting agreement whereby the Consultant was issued 5,000,000 shares of common stock of the Company and received a $20,000 cash payment in exchange for satisfaction of approximately $200,000 in outstanding consulting fees due to the Consultant up through August 31, 2022. The parties also agreed to the reduction of future fees payable to the Consultant from $40,000 per month to $15,000 per month for the period September 2022 through March 2023.

401(K) PLAN (Details Narrative)

401(K) PLAN (Details Narrative)	3 Months Ended
	Jan. 31, 2023 USD ($)
K Plan
Contributions	$ 0